GPCRs have been widely implicated in the control of cardiac function. These receptors couple to heterotrimeric GTP-binding proteins of the Gα~s~, Gα~i~, Gα~q/11~ and Gα~12/13~ families, and transduce the GPCR signal to intracellular targets. Numerous studies have linked Gα~s~ to increased contractility, Gα~q/11~ to pathological hypertrophy^[@R2],[@R3]^, and Gα~i~ to cardioprotection^[@R4]^. APJ is a GPCR identified as the receptor for the adipokine apelin^[@R5],[@R6]^. Apelin-activated APJ signals through Gα~i~ exerting a positive effect on cardiac contractility^[@R7]--[@R9]^ and a vasodilator activity that counteracts angiotensin-II-induced atheroma^[@R10][@R11]^. Apelin administration blunts progression to hypertrophy ([Suppl. Fig. 1](#SD1){ref-type="supplementary-material"} and [Suppl. Tables 2--3](#SD2){ref-type="supplementary-material"}) and apelin-KO mice show susceptibility to heart failure^[@R12]^ (also see [Suppl. Fig. 1](#SD1){ref-type="supplementary-material"} and [Suppl. Table 1](#SD2){ref-type="supplementary-material"}). Thus, apelin and its receptor APJ are emerging as potential therapeutic targets.

We examined the response of APJ knockout mice to sustained pressure overload by transaortic constriction (TAC). Although deletion of APJ resulted in some prenatal lethality ^[@R13],[@R14]^, all viable APJ-KO mice displayed normal adult appearance and cardiovascular parameters at baseline ([Suppl. Table 4](#SD2){ref-type="supplementary-material"}). However, APJ-null animals were resistant to the pathological hypertrophic response to TAC ([Fig. 1a--d](#F1){ref-type="fig"}) observed both in WT and in apelin-KO mice ([Suppl. Fig. 1g--I](#SD1){ref-type="supplementary-material"}). APJ-KO mice responded to TAC by initially increasing cardiac mass but the maladaptive progression to dilated ventricular hypertrophy was blunted shortly after injury ([Suppl. Table 4](#SD2){ref-type="supplementary-material"}). The protective effect persisted long-term ([Fig. 1a, b and g,h](#F1){ref-type="fig"}) in all parameters measured, including diminished cardiomyocyte size ([Fig. 1c, d](#F1){ref-type="fig"}), reduced fibrosis ([Fig. 1e, f](#F1){ref-type="fig"}), sustained cardiac contractility ([Fig. 1g](#F1){ref-type="fig"}) relative to WT and apelin-KO mice ([Suppl. Tables 1, 4](#SD2){ref-type="supplementary-material"}), and reduced heart weight/body weight ratio ([Fig. 1h](#F1){ref-type="fig"}). Baseline cardiac contractility measured as percent fractional shortening (%FS), was approximately 38% across genotypes. After 90 days of TAC, % FS decreased to 22 ± 2% in WT, 23 ± 1% in apelin KO mice, but remained at 34 ± 2% in APJ-KO mice (p=0.01 between APJ-KO and WT) ([Fig. 1g](#F1){ref-type="fig"} and [Suppl. Tables 1, 4](#SD2){ref-type="supplementary-material"}). In summary, both WT and apelin-KO mice presented clear signs of heart failure after 90 days of TAC, while APJ-KO mice were almost unaffected. The maintenance of cardiac function in the APJ-KO demonstrates that the expression of APJ is necessary to elicit heart failure in response to pressure overload.

The different responses of apelin-KO and APJ-KO mice to TAC imply that either apelin can act independently of APJ, or that APJ transduces a signal independently of apelin. We tested the first hypothesis by infusing APJ-KO mice with apelin (285 μg/kg/24h) and examining two readouts: contractility under TAC, and vascular tone. Notably, apelin infusion did not increase cardiac contractility (%FS) in TAC-APJ-KO mice, in contrast to the characteristic improvement seen in TAC-WT animals ([Suppl. Fig. 2a](#SD1){ref-type="supplementary-material"}). In the absence of apelin infusion, endogenous levels of apelin in blood increased after TAC from 1ng/ml to 2ng/ml and that rise was not-different in WT and APJ-KO mice, making it unlikely that the protection achieved in the APJ-KO is due to hyper-activation of apelin signaling ([Suppl. Fig. 2b](#SD1){ref-type="supplementary-material"}). To test vascular tone, systolic and diastolic blood pressures were increased by infusion of Ang-II (1,000 ng/kg/min). Apelin infusion significantly decreased systolic blood pressure in WT animals but not in APJ-KO mice ([Suppl. Fig. 2c--f](#SD1){ref-type="supplementary-material"}), further suggesting that apelin activity requires APJ.

Since the mechanical properties of the heart change dramatically during pressure overload^[@R15]^, and the structurally related angiotensin receptor (AT-1) can act as a mechanosensor^[@R16]^, we asked whether APJ responds to mechanical stretch. Initially these experiments were challenging as cultured cardiomyocytes consistently down-regulate the expression of endogenous APJ ([Suppl. Fig. 3a](#SD1){ref-type="supplementary-material"}), and studies had to be restricted to freshly isolated adult cardiomyocytes. We mimicked the effect of pressure overload by using a carbon fiber (CF) technique^[@R17]^ to stretch cardiomyocytes and evaluated their Frank-Starling Gain (FSG). FSG is a dimensionless metric of the force that can be recruited by stretch^[@R18]^. Freshly isolated adult cardiomyocytes from WT mice displayed a significantly higher FSG than cardiomyocytes from APJ-KO mice ([Fig. 2a--c](#F2){ref-type="fig"}). Treatment with apelin decreased the FSG in WT cardiomyocytes but showed no effect in APJ-KO cells, ([Fig. 2d](#F2){ref-type="fig"}). Therefore, apelin modulated the response to stretch only in cardiomyocytes with APJ receptors.

Engineered cells stably expressing human APJ (APJ-HEK) responded to apelin by increasing the content of pERK ([Fig. 3a, b](#F3){ref-type="fig"}) whereas parental (HEK) cells showed no significant change. Stretch also increased pERK content in cells expressing APJ ([Fig. 3a,b](#F3){ref-type="fig"}). pERK levels, therefore, reflect the cellular response to APJ activation by either stretch or apelin. pERK was therefore used as a simple readout of APJ activation. The Gα~i~ inhibitor PTX blocked the ability of apelin, but not stretch, to induce APJ-dependent phosphorylation of ERK ([Fig. 3a,b](#F3){ref-type="fig"}), first suggesting that separate mechanisms link stretch and apelin to APJ intracellular signaling.

We next examined whether activation of APJ by stretch or apelin differentially modulate G-protein-generated second messengers. Activation of Gα~i~ is associated with inhibition of adenyl-cyclase and reduced cAMP, whereas activation of Gα~s~ increases cAMP^[@R19]^. cAMP did not increase after application of stretch or apelin, arguing against activation of adenyl-cyclase (and Gα~s~) ([Fig. 3c--d](#F3){ref-type="fig"}, no isoproterenol conditions). In contrast, when isoproterenol was used to elevate the intracellular concentration of cAMP^[@R20]^, apelin addition decreased cAMP levels in the APJ-HEK cells ([Fig. 3c](#F3){ref-type="fig"}). This effect of apelin was partially inhibited by PTX, consistent with the involvement of Gα~i~ ([Fig. 3c](#F3){ref-type="fig"}). Apelin did not modify isoproterenol-stimulated cAMP formation in untransfected HEK controls, showing that the decrease is mediated by APJ. These data agree with previous reports^[@R21]^ and demonstrate that Gα~i~ transduces the signal initiated by apelin binding to APJ. In contrast, stretch reduced cAMP in parental HEK as well as in APJ-HEK cells ([Fig. 3d](#F3){ref-type="fig"}), indicating that, although stretch can activate Gα~i~ signaling, this response is not mediated through APJ.

The Gα~16~ subunit couples any activated GPCR to phospholipase C, which results in accumulation of inositol phosphates (IP1), and thus provides a general readout of G-protein activation^[@R22]^. Stretch did not increase IP1 production whereas apelin did so in a dose-responsive manner ([Fig. 3e](#F3){ref-type="fig"}). Importantly, for any given concentration of apelin, stretch consistently reduced G-protein activation ([Figure 3e](#F3){ref-type="fig"}). There was a decrease in maximal levels and a shift in EC~50~ from 5.1 × 10^−9^ to 5.5 × 10^−8^ when both stimuli were applied simultaneously ([Fig. 3e](#F3){ref-type="fig"}). These experiments demonstrate that APJ activation by stretch is largely G-protein independent and that stretch interferes with apelin-mediated G-protein activation by APJ.

Using a β-arrestin/APJ complementation assay, apelin was found to induce a dose-dependent increase in β-arrestin signaling, as expected ([Fig. 3f](#F3){ref-type="fig"}). Stretch in the absence of apelin boosted β-arrestin signaling 2-fold over baseline ([Fig. 3g](#F3){ref-type="fig"}). Notably, stretch increasedβ-arrestin recruitment in response to apelin at all doses tested ([Figure 3g](#F3){ref-type="fig"}). Taken together, stretch causes APJ to signal less effectively/potently via G-proteins, but to more effectively recruit β-arrestin.

In order to investigate whether these distinct mechanisms of APJ action differentially affect cardiac hypertrophy, we examined cardiomyocyte cell growth and the expression of molecular markers of pathological hypertrophy in neonatal rat ventricular cardiomyocytes (NRVC)^[@R23],[@R24]^. NRVC in culture respond to mechanical stretch^[@R25]^, mainly through the angiotensin II receptor AT-1^[@R26]^ and the endothelin1 receptor ET-A^[@R27]^, which are also GPCRs. To test the specific effect of APJ in cardiac stretch/hypertrophy, we used pharmacological inhibitors of AT-1 (100 nM candesartan) and ET-A (300 nM BQ123), hereafter labeled as "inhibitors". To overcome APJ down-regulation during cardiomyocyte culture, we reestablished APJ expression by adenoviral transduction (about 90% efficiency) with either control GFP (Ad-GFP) or an APJ-GFP fusion protein (Ad-APJ-GFP). Hypertrophy was assessed by the characteristic increase in perinuclear immunolocalization of atrial natriuretic factor (ANF) ([Fig. 4a--m](#F4){ref-type="fig"}). Remarkaby, apelin treatment did not increase ANF immunostaining, in Ad-APJ-GFP nor in Ad-GFP-infected cells ([Fig. 4d--f and m](#F4){ref-type="fig"}). In contrast, stretch applied in the presence of inhibitors significantly increased the number of perinuclear ANF^+^ cells in APJ-restored cardiomyocytes (27 ± 1%), but not in control cardiomyocytes infected with Ad-GFP (5.8 ± 2.1%) ([Fig. 4g--I, m](#F4){ref-type="fig"}). Co-stimulation with apelin and stretch reduced the number of ANF^+^ cells ([Fig. 4j--l, m](#F4){ref-type="fig"}). Stretch also induced specific changes in the expression of other molecular markers of hypertrophy, including an increased ratio of βMHC/αMHC ([Fig. 4n](#F4){ref-type="fig"}) and increased cell size ([Fig. 4o](#F4){ref-type="fig"}). Similar to its effects on ANF, the addition of apelin also attenuated effects of stretch on other parameters of hypertrophy ([Fig. 4m--o](#F4){ref-type="fig"}). The induction of ANF by stretch was PTX-insensitive, but the ability of apelin to antagonize stretch-induced hypertrophy was prevented by treatment with PTX ([Fig. 4w](#F4){ref-type="fig"}).

Several control experiments confimed that APJ is directly involved in the response to stretch: NRVC treated with forskolin responded to apelin only upon reconstitution of APJ expression, as monitored by their ability to decrease intracellular cAMP levels ([Fig. 4p](#F4){ref-type="fig"}). The possibility that stretch induces the secretion of factors that might indirectly activate hypertrophy through APJ was considered but appears unlikely since conditioned medium from APJ-transfected cardiomyocytes did not induce ANF expression ([Fig. 4q](#F4){ref-type="fig"}). Moreover, the concentration of apelin in the media remained unchanged (approximately 5ng/ml) with or without stretch ([Fig. 4r](#F4){ref-type="fig"}), and conditioned media from stretched cells could not activate β-arrestin recruitment ([Fig. 4s](#F4){ref-type="fig"}). Single cell analysis of low multiplicity APJ-GFP transduced, cells showed that cardiomyocytes require APJ to induce ANF upon stretch ([Fig. 4t--v](#F4){ref-type="fig"}, note perinuclear ANF immunostaining only in GFP^+^ cells in panel v), further demonstrating that APJ activation through stretch is sufficient to elicit cardiac hypertrophy. Prior studies showed that APJ interacts with AT-1 and apelin antagonizes AT-1 function^[@R11]^. As shown in [Fig 4x](#F4){ref-type="fig"}, in the presence of AT-1 inhibitors, only those cells expressing APJ responded to stretch by significantly increasing perinuclear ANF expression. In the absence of AT-1 inhibitors, APJ-transduced and non-transduced cells reached the same maximal level of ANF expression ([Fig. 4y](#F4){ref-type="fig"}). Thus, blocking AT-1 does not impair the ability of APJ to respond to stretch, indicating that APJ alone is sufficient to transduce a stretch-induced hypertrophy signal.

Importantly, siRNA specific for β-arrestin1 or β-arrestin2 ([Fig. 4z](#F4){ref-type="fig"}) blocked the stretch induction of hypertrophic markers (βMHC/αMHC [Fig. 4z](#F4){ref-type="fig"}, and ANF not shown) with an additive effect when both siRNAs were used together. These data substantiate the model that APJ signaling through β-arrestin mediates stretch-induced myocardial hypertrophy.

**In summary,** the mechano-response of APJ is necessary (blunted hypertrophic response to TAC of APJ-KO mice, [Fig. 1](#F1){ref-type="fig"}) and sufficient (stretch induction of ANF expression occurs in cells expressing APJ, [Fig. 4](#F4){ref-type="fig"}) to trigger myocardial hypertrophy in a β-arrestin-dependent manner ([Fig. 4z](#F4){ref-type="fig"}). Apelin does not induce hypertrophy, but instead blunts stretch-induced hypertrophic induction ([Fig. 4j-l-o,t-y](#F4){ref-type="fig"}), suggesting the ability of apelin to override pathological signaling from stretch. At a mechanistic level, APJ transduces apelin and stretch signaling differently. The response to apelin appears to be G-protein-PTX-sensitive, whereas that induced by stretch is PTX-insensitive and G-protein independent in the absence of exogenous apelin ([Fig 3](#F3){ref-type="fig"}). Stretch profoundly affects apelin signaling, diminishing G-protein activation while augmenting β-arrestin recruitment ([Fig. 3e--g](#F3){ref-type="fig"}). These data indicate that APJ integrates apelin and stretch stimuli, biasing the levels of G-protein signaling versus β-arrestin recruitment accordingly.

These results have implications for the consideration of APJ as a drug target, since APJ/stretch can be pathological. Therefore, a beneficial effect will be obtained not by general apelin receptor agonism, but rather by selectively inhibiting the ability of APJ to respond to mechanical stretch or by blocking its interaction with molecules that initiate pathological signaling cascades.

Summary of Methods {#S1}
==================

All experiments were performed in accordance with relevant guidelines and regulations. The Sanford-Burnham Medical Research Institute's Animal Care & Use Program is accredited by AAALAC International and a Multiple Project Assurance A3053-1 is on file in the OLAW, DHHS.

APJ and apelin KO mice {#S2}
----------------------

APJ-KO mice were obtained from Deltagen. Apelin--KO mice are described elsewhere^[@R13]^. Both APJ and apelin lines (male and female) were in C57Bl/6 genetic background in a 99%--100% purity, as demonstrated by microsatelite analysis (Radil). For detailed methods, see [supplementary information](#SD1){ref-type="supplementary-material"}.
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![APJ-KO mice are protected from hypertrophy after TAC\
**a,** Anatomical view and **b,** Histological sections of WT and APJ-KO mice 90 days after surgery. **c,** Cell membrane staining (wheat germ agglutinin). **d,** Quantification from (c). **e,** Trichrome staining (fibrosis in blue, stars). **f,** quantification of (e). **g,** Fractional shortening (%FS) decreased in WT mice after TAC, but did not change significantly in the APJ-KO mice. APJ-KO mice fail to develop heart failure upon sustained TAC as shown by echocardiographyc analysis. **h,** Heart weight-to-body weight ratio (HW/BW) at baseline and in TAC operated mice, 90 days after surgery (see [Suppl. Table 4](#SD1){ref-type="supplementary-material"} for details). Error bars are SEM.\*p\<0.05 between indicated groups, ANOVA.](nihms380683f1){#F1}

![APJ mediates a stretch response that can be modulated by apelin\
**a--b,** Representative force measurements (arbitrary units) for end-diastolic and end-systolic length-tension relationships in adult cardiomyocytes from WT (a) and APJ-KO (b) mice plotted against diastolic length (normalized to unstretched length). Cells were paced at 1Hz. **c,** Frank-Starling Gain (FSG) attained by dividing the active force by the passive force from experiments in (a) and (b) plotted as a function of diastolic length (n= 8 WT and 7 APJ-KO cardiomyocytes). **d,** Average FSG (at 1.02 sarcomeric length from c) is shown for APJ-KO and WT both with (+) and without (−) 10 nM apelin administration (n=6 for WT+apelin and n=7 for APJ-KO+apelin). Error bars are SEM.](nihms380683f2){#F2}

![Stretch activation of APJ enhances β-arrestin while reducing G-protein signaling\
**a,** Immunoblot and **b,** Quantification of ERK from APJ stably transfected (APJ-HEK) and parental (HEK) cells treated for 5 minutes with 100 nM apelin or stretch in absence or presence of PTX (Gα~i~ inhibitor), n=3. **c,** Effect of 1 μM apelin or **d,** stretch on cAMP levels. 1 μM isoproterenol (iso) was used to artificially elevate cAMP to study Gα~i~ activation, n= 4 (PTX). **e**, G-protein (Gα~q,s,i~ and~12/13~) activation by apelin and effect of stretch (red) in CHO cells expressing APJ and Gα~16~. Receptor stimulation activated the promiscuous Gα~16~, phospholipase-Cβ and caused the accumulation of IP1 (representative of 3 experiments, n=4 samples). **f--g**, Arrestin recruitment to the APJ receptor in response to apelin (black) and stretch (red) by an enzyme complementation assay in CHO cells expressing recombinant APJ and β-arrestin2 (representative of 3 experiments, n=3 samples). (f) Represents full range of β-arrestin binding to APJ under either physiological or pharmacological doses of apelin. (g) Shows the data points for 0 -- 10^−10^ M apelin. RLU= Relative light units. Error bars represent SEM. \*p\<0.05 between indicated groups, ANOVA.](nihms380683f3){#F3}

![APJ activation through mechanical stretch elicits cardiac hypertrophy\
**a--l**, ANF immunostaining (white) and nuclear DAPI staining (blue) of rat neonatal ventricular cardiomyocytes transduced with rat APJ (Ad-APJ-GFP) or control GFP (Ad-GFP, green). **m**, Quantification of from a-l (n=250--350 cells). **n,** qPCR analysis of the ratio between β-- and α--MHCs, as an independent index of hypertrophy, n=3--5 samples. **o**, Mean cell sizes in a-l, n=24 cells. **p,** Responsiveness of transfected cells to apelin treatment, n=4--5. **q**, ANF expression in cardiomyocytes in the presence of conditioned-media from stretched cardiomyocytes (str. media), n=3. **r**, Apelin ELISA of conditioned media (12 h) from cardiomyocytes (CM) non-stretched and stretched. **s**, Apelin standard curve of CHO APJ-β-arrestin interaction assay; red arrows represent the response elicited by 2 samples from (r) **t--v.** Higher magnification image of NRVC showing ANF (white) and APJ (green) expression. White arrow indicates APJ^−^ cells not expressing ANF. **w**, Gα~i~ inhibition with PTX blocked the ability of apelin to prevent ANF expression, n=5. **x-y**, qRT-PCR for ANF in cells treated with (**x**) or without (**y**) inhibitors, n=3. **z**, Diminished expression of hypertrophy markers in Ad-APJ-GFP cardiomyocytes transfected upon knockdown of βarrestin1 (siβARR1), βarrestin2 (siβARR2) or both (siβARR1+2), n=4. Except for (p) and (y) all experiments were performed in the presence of inhibitors of AT-1 (candesartan, 100 nM) and ET-A (BQ123, 300 nM) added one hour prior to stretch and/or apelin treatment until fixation. All are representative experiments performed at least three independent times. Error bars are SEM. \*p\<0.05 between indicated groups, ANOVA.](nihms380683f4){#F4}
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